01—Abstract
Summary
Summary of the 8-K filed November 10, 2025. Cited figures are marked; the original filing is the authoritative source.
Bristol Myers Squibb Company (BMY) has announced the successful completion of a significant public offering of €5.00 billion in aggregate principal amount of senior unsecured notes, issued by its wholly-owned Irish subsidiary, BMS Ireland Capital Funding Designated Activity Company.
The offering comprises notes with maturities ranging from 2030 to 2055 and interest rates from 2.973%a to 4.581%. These notes are fully and unconditionally guaranteed by Bristol Myers Squibb Company. The primary purpose of this capital raise is to fund the company's tender offer to repurchase various series of its outstanding notes, as well as to cover associated fees and expenses.
Any remaining proceeds will be allocated for general corporate purposes. This debt issuance signifies a strategic move by Bristol Myers Squibb to manage its existing debt obligations and optimize its capital structure.
02—Key points
Key Highlights
- BMY subsidiary completed a €5.00 billion public offering of senior unsecured notes.
- The notes have varying maturities from 2030 to 2055 with interest rates ranging from 2.973% to 4.581%.
- The notes are fully and unconditionally guaranteed by Bristol Myers Squibb Company.
- Proceeds will primarily be used to fund a tender offer for outstanding company notes.
- The debt issuance is part of BMY's capital management strategy.
- The offering was made pursuant to a prospectus supplement filed on November 7, 2025.
03—Questions
Frequently Asked Questions
What is the total amount of debt raised by Bristol Myers Squibb in this offering?
Bristol Myers Squibb's subsidiary, BMS Ireland Capital Funding Designated Activity Company, raised a total of €5.00 billion through the public offering of its notes.
How will the proceeds from this debt offering be used?
The proceeds will primarily be used to fund the company's tender offer to repurchase various series of its outstanding notes, pay associated fees and expenses, and for general corporate purposes with any remaining funds.
What is the maturity range and interest rate range for these new notes?
The notes have maturities ranging from November 10, 2030, to November 10, 2055, with annual interest rates varying from 2.973% for the 2030 notes to 4.581% for the 2055 notes.
Is this debt issuance guaranteed by Bristol Myers Squibb?
Yes, the notes are fully and unconditionally guaranteed on a senior unsecured basis by Bristol Myers Squibb Company.
04—Continue